Detalhe da pesquisa
1.
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Cardiovasc Diabetol
; 22(1): 72, 2023 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36978066
2.
Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial.
Scand Cardiovasc J
; 57(1): 2166101, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36723445
3.
Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Circulation
; 141(17): 1360-1370, 2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32098501
4.
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD-11.
Diabetes Obes Metab
; 23(12): 2819-2824, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34463420
5.
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial.
Diabetes Obes Metab
; 23(10): 2279-2288, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34159708
6.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(13): 1228-1239, 2017 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28910237
7.
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Diabetes Obes Metab
; 22(5): 798-806, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31912603
8.
Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.
Cardiovasc Diabetol
; 18(1): 135, 2019 10 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31623625
9.
Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes.
Platelets
; 30(4): 521-529, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-29985735
10.
Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).
Circulation
; 136(13): 1193-1203, 2017 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28626088
11.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 373(3): 232-42, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26052984
12.
Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Am Heart J
; 187: 1-9, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28454792
13.
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Diabetes Obes Metab
; 19(6): 791-799, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28093841
14.
Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Diabetes Obes Metab
; 19(1): 78-86, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27607571
15.
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
Lancet
; 383(9922): 1059-66, 2014 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24361242
16.
Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 377(25): 2502, 2017 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29262286
17.
Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist.
Circulation
; 137(12): 1218-1220, 2018 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29555706
18.
Effect of nateglinide on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1463-76, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228402
19.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
N Engl J Med
; 362(16): 1477-90, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20228403
20.
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Am Heart J
; 166(6): 983-989.e7, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24268212